Bristol-Myers Squibb (NYSE:BMY) announced today that BARACLUDE® (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease.

Paris (PRWEB) March 7, 2011

Bristol-Myers Squibb (NYSE:BMY) announced today that BARACLUDE® (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease.

BARACLUDE® was already approved in Europe in June 2006 for use in adult patients with CHB with compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.

This approval grants BARACLUDE® marketing authorisation in the 27 countries of the European Union. in the U.S., the Food and Drug Administration (FDA) approved the decompensated indication for BARACLUDE® in October 2010.

Decompensated liver disease is characterised by failure of the liver to maintain adequate function, usually due to severe scarring, leading to fibrosis and/or cirrhosis caused by chronic liver inflammation.¹ it represents the end stage of hepatitis. Natural history data demonstrate that up to 40% of patients with CHB develop cirrhosis over their lifetimes, at a reported rate of 2-6% per year. Among CHB patients with cirrhosis, 3-5% per year progress to decompensated cirrhosis and 2-5% develop hepatocellular carcinoma (HCC).²,³ Currently, the median survival rate in decompensated patients is two to three years, with only 28% of patients surviving for more than five years.¹,⁴

Once liver disease progresses to the decompenstated stage, a liver transplant is often necessary.

“The approval of this additional indication is an important milestone for CHB patients living with decompensated liver disease, a difficult to treat population whose mortality rates are high,” said Professor Jorg Petersen. “The data used to support this indication shows that BARACLUDE® is efficacious in treating decompensated patients.”

This approval is based on a randomised, open-label, multi-centre study (ETV-048) that compared the efficacy & safety of BARACLUDE® (1.0 mg once daily) with adefovir (10.0 mg once daily) administered in patients with HBeAg positive or negative CHB who had evidence of liver decompensation.

Data demonstrated that BARACLUDE® showed greater viral suppression compared to adefovir at 24 and 48 weeks following treatment initiation. At 48 weeks, 57% (57/100) of patients treated with BARACLUDE® achieved an undetectable viral load (d300 copies/ml) compared to 20% (18/91) of patients on adefovir.

ETV-048 Study ResultsThe 048 study evaluated 191 patients who were either HBeAG-positive or HBeAG-negative. Patients were either treatment-naïve or had been previously treated excluding pre-treatment with BARACLUDE®, adefovir or tenofovir.

Patients were randomised to receive BARACLUDE® (1.0 mg once daily) or adefovir (10.0 mg once daily) and were analysed through 48 weeks.

Baseline demographics were similar for both groups. Importantly, at baseline, patients had a mean CPT (child-pugh score) of 8.81 in the BARACLUDE® arm and 8.35 in the adefovir arm, and the mean MELD (Model for end stage Liver Disease) score was 17.1 and 15.3, respectively. both of these parameters measure the severity of hepatic decompensation.

The mean age of the study population was 52 years and the majority of the subjects were male (74%) and either Asian (54%) or Caucasian (33%).⁵

In the primary efficacy endpoint of mean change from baseline in serum HBV DNA at Week 24, BARACLUDE® was superior to adefovir (-4.48 versus -3.40; p < 0.0001).

Secondary efficacy endpoints included mean change from baseline in serum HBV DNA at Week 48 (-4.66 in the BARACLUDE® arm and -3.90 in the adefovir arm). in addition a greater proportion of patients on BARACLUDE® achieved an undetectable viral load compared to patients on adefovir at 48 weeks: 57% (57/100) versus 20% (18/91), respectively. Also patients on the BARACLUDE® arm decreased their MELD score from baseline by -2.6% versus -1.7% in the adefovir arm at Week 48, even though baseline MELD score had been higher with 17.1 for BARACLUDE® than 15.3 for adefovir. Further the normalization of ALT (Alanine Aminotransferase enzyme) was achieved to a higher proportion in the BARACLUDE®-treated patients (d1 x Upper Limit of Normal) at Week 48 [63% (49/78)] compared with adefovir-treated patients [46% (33/71)].

The time to onset of HCC or death was comparable in the two treatment groups; on-study cumulative death rates were 23% (23/102) and 33% (29/89) for patients treated with BARACLUDE® and adefovir, respectively; and on-study cumulative rates of HCC were 12% (12/102) and 20% (18/89) for BARACLUDE® and adefovir, respectively.

BARACLUDE® was generally well tolerated and safety results were comparable between the treatment groups and consistent with those previously reported for a population with decompensated liver disease. Serious adverse events occurred in 69% of the BARACLUDE® patients and 66% of the adefovirpatientsand discontinuations due to adverse events occurred in 7% of the Baraclude patients and 6 % of the adefovir patients.⁵

Important Information About BARACLUDE®

Discovered at Bristol-Myers Squibb, BARACLUDE® is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:

• Compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.
• Decompensated liver disease.

a higher rate of serious hepatic adverse events (regardless of causality) has been observed in patients with decompensated liver disease, in particular in those with Child-Turcotte-Pugh (CTP) class C disease, compared with rates in patients with compensated liver function. in addition, patients with decompensated liver disease may be at higher risk for lactic acidosis and specific renal adverse events such as hepatorenal syndrome. Clinical and laboratory parameters should be closely monitored in this patient population.

*For full prescribing information for BARACLUDE®, please consult the Summary of Product Characteristics.

About Chronic Hepatitis B (CHB)Chronic hepatitis B is a serious global health issue. Worldwide, more than 2 billion people have been in contact with the hepatitis B virus and approximately 350 million people are chronically infected.⁶

About Decompensated Liver DiseaseDecompensated liver disease is characterised by failure of the liver to maintain adequate function, often due to severe scarring leading to fibrosis and/or cirrhosis caused by chronic liver inflammation.¹ Symptoms of liver decompensation can include but are not limited to: jaundice (yellowing of the skin or eyes), ascites (swollen abdomen from abnormal accumulation of fluid), oesophageal varices (distorted blood vessels that may cause potentially fatal bleeding), and hepatic encephalopathy (neuropsychiatric abnormality resulting in personality changes, intellectual impairment and reduced levels of consciousness).¹

About Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.

BARACLUDE® (entecavir) is a registered trademark of Bristol-Myers Squibb Company.

Contact:Media: Annie Simond, office: +33 1 58 83 65 66, annie(dot)simond(at)bms(dot)com

References¹ D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 2006; 44: 217–31. ² Chu C-M and Liaw Y-F. Hepatitis B virus-related cirrhosis: Natural history and treatment. Seminars in Liver Disease 2006;26(2):142-152.³ Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-S50.⁴ Fattovich G, Pantalena M, Zagni I et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. am. J. Gastroenterol. 2002; 97: 2886–95.⁵ Y. Liaw, et al. Efficacy and Safety of Entecavir versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation. Abstract and Poster 442. AASLD 2009.⁶ World Helath Organization Web site. Fact sheet N• 204. who.int/mediacentre/factsheets/fs204/en/. Accessed 3 December 2010.

###

Annie SimondBristol-Myers Squibb+33 1 58 83 65 66Email Information

Results from multiple Phase 1 studies evaluating the interaction between telaprevir and ritonavir-boosted protease inhibitors, NNRTIs and NRTIs (Abstract #119)

— Telaprevir slightly increased the exposure to ritonavir-boosted

atazanavir. Ritonavir-boosted atazanavir slightly reduced the exposure

to telaprevir. This interaction was not considered to be clinically

significant. a HIV regimen that includes ritonavir-boosted atazanavir is

being evaluated in an ongoing Phase 2 study of telaprevir-based therapy

in people infected with both hepatitis C and HIV.

— an interaction between efavirenz and telaprevir (750 mg, every eight

hours) was observed, but a higher dose of telaprevir (1,125 mg, every

eight hours) could largely offset the interaction. This higher dose of

telaprevir is being evaluated as part of an ongoing Phase 2 study in

people co-infected with hepatitis C and HIV who are also receiving

efavirenz as part of their HIV treatment.

— Significant interactions were observed between telaprevir and

boosted-lopinavir, darunavir and fosamprenavir, such that

telaprevir-based combination therapy is not currently being evaluated

for people taking these HIV medicines.

Telaprevir is an investigational, oral inhibitor that acts directly on the HCV protease, an enzyme essential for viral replication. to date, more than 2,500 people with genotype 1 hepatitis C have received telaprevir in Phase 2 and Phase 3 studies.

Vertex is developing telaprevir in collaboration with Tibotec BVBA and Mitsubishi Tanabe Pharma. Vertex has rights to commercialize telaprevir in North America. Through its affiliate, Janssen, Tibotec has rights to commercialize telaprevir in Europe, South America, Australia, the Middle East and certain other countries. Mitsubishi Tanabe Pharma has rights to commercialize telaprevir in Japan and certain Far East countries.

Telaprevir has been granted priority review by the U.S. Food and Drug Administration (FDA) and by Health Canada and accelerated assessment by the European Medicines Agency for the treatment of people chronically infected with genotype 1 hepatitis C virus (HCV). the applications include data from three registrational studies, ADVANCE, ILLUMINATE and REALIZE, which evaluated telaprevir in people with hepatitis C who were new to treatment as well as those who did not achieve a viral cure after treatment with currently available medicines. for complete information on the clinical trials or a fact sheet on the trial designs visit: vrtx.com/press.cfm.

About Hepatitis C and HIV Co-Infection

there are 1 million people living with HIV in the United States.(2) It’s estimated that up to 30 percent of people living with HIV/AIDS are also infected with hepatitis C.(3) there have been dramatic improvements in the treatment of HIV and the prognosis for people living with HIV. However, liver disease progresses more rapidly in people co-infected with hepatitis C and HIV, with an increased rate of progression to cirrhosis, decompensated liver disease, hepatocellular carcinoma and death.(3,4,5)

Hepatitis C is a serious liver disease caused by the hepatitis C virus, which is spread through direct contact with the blood of infected people and ultimately affects the liver.(6) Chronic hepatitis C can lead to serious and life-threatening liver problems, including liver damage, cirrhosis, liver failure or liver cancer.(6) though many people with hepatitis C may not experience symptoms, others may have symptoms such as fatigue, fever, jaundice and abdominal pain.(6) Approximately 60 percent of genotype 1 hepatitis C patients who undergo treatment with an initial 48-week regimen with pegylated-interferon and ribavirin, the currently approved medicines, do not achieve SVR,(7,8,9) or viral cure.(10) if treatment is not successful and a person does not achieve a viral cure, they remain at an increased risk for progressive liver disease.(11,12,13,14,15)

more than 170 million people worldwide are chronically infected with hepatitis C. In the United States, nearly 4 million people have chronic hepatitis C and 75 percent of them are unaware of their infection.(16) the majority of people with hepatitis C in the United States were born between 1946 and 1964, accounting for two of every three people with chronic hepatitis C.(15) Hepatitis C is the leading cause of liver transplantations in the United States and is reported to contribute to 4,600 to 12,000 deaths annually.(12) by 2029, total annual medical costs in the United States for people with hepatitis C are expected to more than double, from $30 billion in 2009 to approximately $85 billion.(15)

PEGASYS(R) and COPEGUS(R) are registered trademarks of Hoffman-LA Roche.

Reyataz(R) is a registered trademark of Bristol-Myers Squibb.

Atripla(R) is a registered trademark of Bristol-Myers Squibb and Gilead Sciences, LLC.

Special Note regarding Forward-looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding (i) the interim results being encouraging because they showed a high proportion of people in the study had a rapid response to telaprevir; (ii) Vertex’s plan to use what it is learning from the study to inform a Phase 3 co-infection study of telaprevir planned for the end of 2011; (iii) expectations that final SVR results from the study will be available in 2012 and (iv) the possibility that a higher dose of telaprevir could largely offset the interaction observed between efavirenz and telaprevir. While Vertex believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. those risks and uncertainties include, among other things, the risks that efforts to develop telaprevir as a treatment for patients co-infected with genotype 1 HCV and HIV may not proceed due to technical, scientific, commercial, financial or other reasons; that final outcomes, including SVR rates, from this clinical trial and any future clinical trials of telaprevir in patients with HCV-HIV co-infection may not be favorable; that RVR and cEVR may not be predictive of SVR in patients with HCV-HIV co-infection and the other risks listed under Risk Factors in Vertex’s annual report and quarterly reports filed with the Securities and Exchange Commission and available through Vertex’s website at vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

Vertex creates new possibilities in medicine. Our team aims to discover, develop and commercialize innovative therapies so people with serious diseases can lead better lives.

Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, epilepsy and other life-threatening diseases.

Founded more than 20 years ago in Cambridge, MA, we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada.

for more information and to view Vertex’s press releases, please visit vrtx.com.

References: (1) 2010 Guidelines for Antiretroviral Treatment of HIV From the International AIDS Society-USA Panel JAMA. 2010;304(17):1897. (2) Centers for Disease Control and Prevention. HIV/AIDS and Viral Hepatitis. available at cdc.gov/hepatitis/Populations/hiv.htm. Accessed February 17, 2011. (3) Health Resources and Services Administration. Care and Treatment for Hepatitis C and HIV Co-infection. available at hab.hrsa.gov/tools/coinfection/coinfectionsub.html and hab.hrsa.gov/tools/coinfection/index.html Accessed February 28, 2011. (4) Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier a, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30(4):1054-58. (5) Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. CID 2004;38:128-33. (6) Martinez-Sierra C, Arizcorreta a, Diaz F, Roldan R, Martin-Herrera M, Perez- Guzman E, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. CID 2003;36:491-8. (7) Centers for Disease Control and Prevention. Hepatitis C Fact Sheet: CDC Viral Hepatitis. available at: cdc.gov/hepatitis/HCV/PDFs/HepCGeneralFactSheet.pdf. Accessed May 25, 2010. (8) Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965. (9) Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982. (10) McHutchison JG, Lawitz EJ, Shiffman ML, et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593. (11) Ghany MG, Strader DB, Thomas DL, Seeff, LB. Diagnosis, management and treatment of hepatitis C; an update. Hepatology. 2009;49 (4):1-40. (12) Morgan TR, Ghany MG, Kim HY, Snow KK, Lindsay K, Lok AS. Outcome of sustained virological responders and non-responders in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial. Hepatology.

(MORE TO FOLLOW) Dow Jones Newswires

• print this
• email alerts

More Like This…
• Reuters launches Elektron at Nasdaq OMX Nordic markets

  Based at the NASDAQ OMX co-location site in Sweden, Elektron will provide trading firms with ultra low latency connectivity to European real-time pricing information. NASDAQ OMX will leverage a connection to the Elektron network for its new Nordic Smart or…continued

• BATS Global Markets names new chief financial officer & VP

  BATS Global Markets has announced the appointment of Brian Schell as chief financial officer and senior vice president, effective immediately.Mr. Schell arrives at BATS with more than 20 years of experience in the financial services industry, including 16…continued

• The Algo Group provides connectivity and colocation to LSE's Millennium

  the Algo Group has announced that it has gone live as a provider of connectivity and colocation services to the London Stock Exchange Group’s new low latency trading platform, Millennium Exchange.This will enable the high frequency, latency sensitive…continued

• Liquidnet appoints Andrew Geissler to Equity Capital Markets team

  Liquidnet has announced that Andrew Geissler has joined the company as part of the Equity Capital Markets (ECM) & Issuer Services business and will report directly to Steve Greenblatt, Head of Issuer Services and ECM.”Liquidnet’s institutional marketplace,…continued

• Rafferty Capital Markets selects SunGard?s Valdi

  Rafferty Capital Markets LLC, a registered broker dealer, has selected SunGard’s Valdi Order Management System (OMS) and Valdi Direct Market Access (DMA) for its institutional trading business. Valdi aims to help Rafferty reduce latency, improve exe…continued

• Copyright © Automated Trader ltd 2011

• Popular Searches
• Headlines Archive
• All AlgoWorld Listings
• Privacy Policy
• Sitemap

click here to return to the top of the page

Paris (ots/PRNewswire) – Bristol-Myers Squibb announced today that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease. BARACLUDE(r) was already approved in Europe in June 2006 for use in adult patients with CHB with compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. this approval grants BARACLUDE(r) marketing authorisation in the 27 countries of the European Union. In the U.S., the Food and Drug Administration (FDA) approved the decompensated indication for BARACLUDE(r) in October 2010. Decompensated liver disease is characterised by failure of the liver to maintain adequate function, usually due to severe scarring, leading to fibrosis and/or cirrhosis caused by chronic liver inflammation.[1] It represents the end stage of hepatitis. Natural history data demonstrate that up to 40% of patients with CHB develop cirrhosis over their lifetimes, at a reported rate of 2-6% per year.[1] among CHB patients with cirrhosis, 3-5% per year progress to decompensated cirrhosis and 2-5% develop hepatocellular carcinoma (HCC).[2,3] Currently, the median survival rate in decompensated patients is two to three years, with only 28% of patients surviving for more than five years.[1,4] once liver disease progresses to the decompenstated stage, a liver transplant is often necessary. “The approval of this additional indication is an important milestone for CHB patients living with decompensated liver disease, a difficult to treat population whose mortality rates are high,” said Professor Jorg Petersen. “The data used to support this indication shows that BARACLUDE(r) is efficacious in treating decompensated patients.” this approval is based on a randomised, open-label, multi-centre study (ETV-048) that compared the efficacy&safety of BARACLUDE(r) (1.0 mg once daily) with adefovir (10.0 mg once daily) administered in patients with HBeAg positive or negative CHB who had evidence of liver decompensation. Data demonstrated that BARACLUDE(r) showed greater viral suppression compared to adefovir at 24 and 48 weeks following treatment initiation. At 48 weeks, 57% (57/100) of patients treated with BARACLUDE(r) achieved an undetectable viral load (less than or equal to 300 copies/ml) compared to 20% (18/91) of patients on adefovir. ETV-048 Study Results The 048 study evaluated 191 patients who were either HBeAG-positive or HBeAG-negative. Patients were either treatment-naive or had been previously treated excluding pre-treatment with BARACLUDE(r), adefovir or tenofovir. Patients were randomised to receive BARACLUDE(r) (1.0 mg once daily) or adefovir (10.0 mg once daily) and were analysed through 48 weeks. Baseline demographics were similar for both groups. Importantly, at baseline, patients had a mean CPT (child-pugh score) of 8.81 in the BARACLUDE(r) arm and 8.35 in the adefovir arm, and the mean MELD (Model for end stage Liver Disease) score was 17.1 and 15.3, respectively. Both of these parameters measure the severity of hepatic decompensation. The mean age of the study population was 52 years and the majority of the subjects were male (74%) and either Asian (54%) or Caucasian (33%).[5] In the primary efficacy endpoint of mean change from baseline in serum HBV DNA at Week 24, BARACLUDE(r) was superior to adefovir (-4.48 versus -3.40; p < 0.0001). Secondary efficacy endpoints included mean change from baseline in serum HBV DNA at Week 48 (-4.66 in the BARACLUDE(r) arm and -3.90 in the adefovir arm). In addition a greater proportion of patients on BARACLUDE(r) achieved an undetectable viral load compared to patients on adefovir at 48 weeks: 57% (57/100) versus 20% (18/91), respectively. Also patients on the BARACLUDE(r) arm decreased their MELD score from baseline by -2.6% versus -1.7% in the adefovir arm at Week 48, even though baseline MELD score had been higher with 17.1 for BARACLUDE(r) than 15.3 for adefovir. Further the normalization of ALT (Alanine Aminotransferase enzyme) was achieved to a higher proportion in the BARACLUDE(r)-treated patients (less than or equal to 1 x Upper Limit of Normal) at Week 48 [63% (49/78)] compared with adefovir-treated patients [46% (33/71)]. The time to onset of HCC or death was comparable in the two treatment groups; on-study cumulative death rates were 23% (23/102) and 33% (29/89) for patients treated with BARACLUDE(r) and adefovir, respectively; and on-study cumulative rates of HCC were 12% (12/102) and 20% (18/89) for BARACLUDE(r) and adefovir, respectively. BARACLUDE(r) was generally well tolerated and safety results were comparable between the treatment groups and consistent with those previously reported for a population with decompensated liver disease. Serious adverse events occurred in 69% of the BARACLUDE(r) patients and 66% of the adefovirpatientsand discontinuations due to adverse events occurred in 7% of the Baraclude patients and 6 % of the adefovir patients.[5] Important Information about BARACLUDE(r) Discovered at Bristol-Myers Squibb, BARACLUDE(r) is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: – Compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. – Decompensated liver disease. a higher rate of serious hepatic adverse events (regardless of causality) has been observed in patients with decompensated liver disease, in particular in those with Child-Turcotte-Pugh (CTP) class C disease, compared with rates in patients with compensated liver function. In addition, patients with decompensated liver disease may be at higher risk for lactic acidosis and specific renal adverse events such as hepatorenal syndrome. Clinical and laboratory parameters should be closely monitored in this patient population. * for full prescribing information for BARACLUDE(r), please consult the Summary of Product Characteristics. about Chronic Hepatitis B (CHB) Chronic hepatitis B is a serious global health issue. Worldwide, more than 2 billion people have been in contact with the hepatitis B virus and approximately 350 million people are chronically infected.[6] about Decompensated Liver Disease Decompensated liver disease is characterised by failure of the liver to maintain adequate function, often due to severe scarring leading to fibrosis and/or cirrhosis caused by chronic liver inflammation.[1] Symptoms of liver decompensation can include but are not limited to: jaundice (yellowing of the skin or eyes), ascites (swollen abdomen from abnormal accumulation of fluid), oesophageal varices (distorted blood vessels that may cause potentially fatal bleeding), and hepatic encephalopathy ( neuropsychiatric abnormality resulting in personality changes, intellectual impairment and reduced levels of consciousness).[1] about Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. BARACLUDE(R) (entecavir) is a registered trademark of Bristol-Myers Squibb Company. References 1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 2006; 44: 217-31. 2. Chu C-M and Liaw Y-F. Hepatitis B virus-related cirrhosis: Natural history and treatment. Seminars in Liver Disease 2006;26(2):142-152. 3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-S50. 4. Fattovich G, Pantalena M, Zagni I et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. 2002; 97: 2886-95. 5. Y. Liaw, et al. Efficacy and Safety of Entecavir versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation. Abstract and Poster 442. AASLD 2009. 6. World Helath Organization Web site. Fact sheet N- 204. who.int/mediacentre/factsheets/fs204/en/. Accessed 3 December 2010.ots Originaltext: Bristol-Myers Squibb GmbH&Co.KG aA Im Internet recherchierbar: presseportal.deContact: Contact: Media: Annie Simond, office: +33-1-58-83-65-66,© 2011 news aktuell